Shares of Novo Nordisk (NVO Quick QuoteNVO - Free Report) rose 4.1% on Tuesday following its announcement of a new multi-month subscription program for its blockbuster GLP-1 therapy, Wegovy (semaglutide). The program is designed for eligible self-pay patients who enroll through select telehealth providers, offering a lower and more predictable monthly cost. The initiative is intended to reduce pricing uncertainty and improve access to long-term, FDA-approved obesity treatment.

Wegovy is approved as an injection as well as an oral tablet for chronic weight management in adults with obesity when used alongside diet and exercise, and has also demonstrated cardiovascular benefits, including reducing the risk of major adverse events such as heart attack, stroke, or death in certain patients with established heart disease. By introducing a structured subscription model, NVO seeks to address affordability challenges that can hinder treatment initiation and adherence.

The program builds on Novo Nordisk’s broader strategy to meet patients where they increasingly seek care, while expanding affordable access to authentic, FDA-approved Wegovy. It is designed to reduce treatment barriers by offering a simple, consistent and cost-effective pathway for eligible patients, supported by predictable monthly pricing, multi-month subscription options and access via select telehealth providers. The initiative aims to improve treatment initiation and adherence, ultimately supporting more sustainable weight management outcomes.

NVO’s Wegovy Subscription Program in Detail

Novo Nordisk’s first and only subscription program for FDA-approved Wegovy was launched on March 31, 2026, initially through telehealth platforms such as Ro, WeightWatchers and LifeMD, with additional providers, including Hims & Hers and Sesame, expected to join later. The offering is targeted at eligible self-pay patients. It is designed to deliver meaningful cost savings, with potential annual reductions of up to $600 for the oral formulation and up to $1,200 for the injectable version under a 12-month plan. Patients are required to enroll through participating telehealth providers, who will determine eligibility and provide program-specific details.

The program provides flexible subscription options spanning three, six, or 12 months, with longer commitments offering lower monthly pricing. For the injectable Wegovy pen across multiple dose strengths, pricing ranges from $329 per month under a three-month plan to $249 per month under a 12-month plan. Similarly, the oral formulation is priced between $289 and $249 per month for the 9 mg and 25 mg doses, depending on subscription duration, with additional lower-dose options offered at reduced rates and subject to time-limited promotional pricing. The recently approved Wegovy HD injection 7.2 mg is expected to be added to the subscription plan at a later stage.

In the past six months, Novo Nordisk shares have plunged 37.4% against the industry’s 6.1% growth.

Image Source: Zacks Investment Research

Novo Nordisk noted that promotional offers are separate from the subscription structure and may vary across telehealth platforms, requiring patients to review terms directly with providers.

Beyond telehealth channels, Wegovy continues to be accessible through a broad distribution network that includes more than 70,000 pharmacies in the United States, as well as NVO’s online pharmacy, NovoCare Pharmacy. For patients with commercial insurance, existing savings programs may reduce out-of-pocket costs to as low as $25 per month, further expanding access to treatment.

In 2025, Novo Nordisk’s sales and profitability came under notable pressure, driven by slowing demand for Wegovy amid the widespread availability of compounded GLP-1 alternatives in the United States that proliferated during prior supply shortages. The company also faced intensifying competition from Eli Lilly (LLY Quick QuoteLLY - Free Report) , whose GLP-1 therapy Zepbound (tirzepatide) has gained traction and eroded Novo Nordisk’s market share over the past year. Meanwhile, Lilly’s oral GLP-1 candidate, orforglipron, is under FDA review and, if approved, would compete directly with the oral version of Wegovy, intensifying rivalry in the rapidly expanding obesity and diabetes treatment markets.

Against this backdrop, Novo Nordisk’s newly introduced Wegovy subscription model — alongside increased FDA crackdown on compounded semaglutide — has begun to meaningfully curb the impact of off-market alternatives, potentially supporting a recovery in Wegovy demand. While competitive pressures from Eli Lilly remain significant, the company believes that improved affordability, broader access through telehealth partnerships, and enhanced treatment continuity could help stabilize growth and gradually reclaim lost market share.

Novo Nordisk A/S Price and Consensus

Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote

NVO’s Zacks Rank & Stocks to Consider

Novo Nordisk currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX Quick QuoteCPRX - Free Report) and ADMA Biologics (ADMA Quick QuoteADMA - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have decreased from $2.55 to $2.51. CPRX shares have gained 18.9% over the past six months.

Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.

Over the past 60 days, estimates for ADMA Biologics’ 2026 EPS have increased from 85 cents to 96 cents. ADMA shares have plummeted 37.9% over the past six months.

ADMA Biologics’ earnings beat estimates in one of the trailing three quarters, matched once and missed on the remaining occasion, with the average negative surprise being 1.79%.